The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation.
Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
🎥 Rupert Bartsch of @CCC_Vienna talks on the ELEANOR interim analysis: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer
The approval of #elacestrant for #mbc opens up a debate about the fda approval process. A clear benefit in esr1m tumors and at least equivalence in nonmutated. But oral therapy with mostly grade 1 and 2 toxicity. So why can’t physicians and patients have another oral option?
Hot off the presses: FIRST ORAL SERD APPROVED FOR HR+/HER2- metastatic breast cancer! Elacestrant (Orserdu) approved for ESR1 mutated HR+ MBC after one line of ET. More options for our patients, one more step forward!
In high-grade #ovariancancer
The magnitude of benefit from olaparib may be related to the location of the mutation in BRCA1/2 🧬🧬
@Annals_Oncology @myESMO @OncoAlert @VJOncology @ESGO_society @acog @ASCO @agz_eriksson @IGCSociety @SGO_org @VukovicPetra
https://doi.org/10.1016/j.annonc.2022.11.003
American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation.
Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
🎥 Rupert Bartsch of @CCC_Vienna talks on the ELEANOR interim analysis: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer
The approval of #elacestrant for #mbc opens up a debate about the fda approval process. A clear benefit in esr1m tumors and at least equivalence in nonmutated. But oral therapy with mostly grade 1 and 2 toxicity. So why can’t physicians and patients have another oral option?
Hot off the presses: FIRST ORAL SERD APPROVED FOR HR+/HER2- metastatic breast cancer! Elacestrant (Orserdu) approved for ESR1 mutated HR+ MBC after one line of ET. More options for our patients, one more step forward!
In high-grade #ovariancancer
The magnitude of benefit from olaparib may be related to the location of the mutation in BRCA1/2 🧬🧬
@Annals_Oncology @myESMO @OncoAlert @VJOncology @ESGO_society @acog @ASCO @agz_eriksson @IGCSociety @SGO_org @VukovicPetra
https://doi.org/10.1016/j.annonc.2022.11.003
Lung Cancer Sessions: BTOG 2022 highlights & UK lung cancer care
Watch leading UK lung cancer experts Sanjay Popat, Alastair Greystoke, Anna Minchom & Robert Rintoul discuss the important learnings from the British Thoracic Oncology Group (BTOG) Annual Meeting 2022.
Learn about the current status of lung cancer care in the UK, novel therapeutic targets and the deployment of genomic medicine in the UK.